Ozempic and Wegovy have received a lot of publicity as revolutionizing treatment options for obesity. Both medications form a class of GLP-1 receptor agonists, which mimic a hormone in the body called glucagon-like peptide-1 and are involved in the regulation of appetite and blood sugar. Indeed, in initial clinical studies, the majority of those on the drugs lost 15% to 22% of body weight, hence much optimism. For most patients, these medications are underwhelming for about 20% of patients due to minimal weight loss or other challenges.

Take a closer look at why the weight loss drugs may not work for everyone, together with what options exist when they don't deliver the expected outcomes.

Why Weight Loss Drugs May Not Work

While GLP-1 receptor agonists have produced phenomenal responses in a majority of patients, it remains a reality that these drugs work differently for different people. Here's why:

1. Genetic and Hormonal Variability

Weight loss medications interact with complex systems in the body that differ from person to person. Genetics, hormones, and individual brain responses to energy regulation play significant roles in determining how a person responds to drugs like Ozempic and Wegovy.

2. Underlying Medical Conditions

Other conditions, such as sleep apnea, may be prevalent and prevent or delay the achievement of weight loss goals. Prescription drugs like antidepressants, steroids, or contraceptives are other medications that can nullify weight loss medication benefits.

3. Unrealistic Expectations

Often, they come to these medications with enormous hopes; expecting the promised rapid and dramatic weight loss. Progress creates disappointment if it has not stalled. In patients who rigidly follow recommended lifestyle modifications, frustration and disappointment are most common.

Why it is Important to Identify Non-responders

For most patients, the effectiveness of GLP-1 receptor agonists is evident within a few weeks of treatment. Weight loss typically begins within a few weeks of initiating therapy and tends to increase with dosage. However, some patients respond very little, if at all, despite strict adherence to their regimen.

For nonresponders, this can feel like a dead end. However, understanding the unique complexities of obesity is essential. This condition stems from brain dysfunction, and the pathways that contribute to weight regulation differ among individuals.

Alternative Treatment Options

When Ozempic or Wegovy doesn’t yield desired results, there are still many paths to explore:

1. Switching to Another GLP-1 Drug

For example, some patients who don't respond well to one GLP-1 receptor agonist might find success with another drug in the same class. Newer medications, such as Zepbound, target other hormone pathways and seem promising even for those not responsive to earlier drugs.

2. Use of Older Medications

While there is much to say about newer drugs, older treatments can still be useful and work for some patients. One can also seek the help of a medical provider specializing in obesity treatments in order to identify the best alternatives.

3. Lifestyle Changes

Diet, exercise, sleep, and stress management continue to be integral components of any weight loss program. New changes may be small but can make an enormous difference in one's health and success.

4. Medical Management of Obesity

It is a complex disorder, and most patients should receive a multidisciplinary treatment. Collaboration with an obesity-aware doctor may mean access to tailored treatment plans, ranging from psychological support all the way to metabolic testing, and many others.

Why Side Effects of Weight Loss Drug Ozempic May Be a Barrier

For others, side effects like nausea, vomiting, or diarrhea hinder them from continuing with these drugs. These symptoms often reduce as the body becomes accustomed, but for some, they might be severe enough to stop treatment altogether. In those instances, alternative drugs or procedures become vital to find.

Long-term effects of Ozempic or Wegovy on the Brain

Another largely unexplored area relates to GLP-1 drugs' long-term effects on the brain's regulation of hunger and satiety. Although GLP-1 drugs suppress appetite and can lead to effective weight loss, emerging research suggests that they may also affect brain reward mechanisms, changing the way patients experience foods.

This aspect could prove of paramount significance in the future treatment of obesity. Perhaps GLP-1 receptor agonists do indeed affect and rewire the brain's reward pathways and will thus provide sustained benefits beyond discontinuation. However, more research is required to understand this phenomenon fully.

While for many, Ozempic and Wegovy have revolutionized obesity treatment, these are certainly not a one size fits all. Nonresponders need not lose hope- alternative strategies and medications abound. A consultation with an obesity expert healthcare provider is essential to put together a comprehensive, tailored treatment plan.

The route toward effective weight loss may be challenging, but with the evolution of obesity medicine and a better understanding of individual needs, there is a path forward for everyone.

Nicotine pouches have become popular in the UK, show many studies, this is especially true in the case of young adults.

In fact, a new study done by the researches from University College London (UCL) has found that in the last five years, there has been an increase from 0.1 per cent to 1 per cent of adults using nicotine pouches. This means, around 522,000 more people in the UK have started using the pouches.

How Does A Nicotine Pouch Work?

The pouches are placed between the lip and gum and it releases nicotine slowly. The pouches are also available in variety of flavors, with sweeteners and plant-based fibers. It does not contain tobacco like vapes do and usually are considered to be a healthier alternative to smoking.

Health and Me ran a fact check on whether it truly is safer than smoking, and here is what we found.

Are Nicotine Pouches Safer Than Smoking?

"This risks are substantially less than some other nicotine products like smoking, because there is no tobacco and there is no combustion," said Dr Harry Tattan-Birch, the lead author of the study, to Mornings with Ridge and Frost.

"And we know the combustion of tobacco is the thing that causes most of the diseases related to smoking," he says.

However, he and his team has warned that while it may not cause serious illness like tobacco can, young people could have a negative impact in their lungs and brains, as they are still in developing stage. This makes them more sensitive to the effects of nicotine, and it could become difficult to stop using it.

A UCL research fellow earlier told Sky News that while nicotine pouches are far less harmful than smoking, their long-term effects remain unclear because they are relatively new. Drawing on what is known about their contents, she noted they are not risk-free, as users are still exposed to some toxic substances, albeit at much lower levels.

Who Are Using These Nicotine Pouches?

Researchers from UCL, supported by Cancer Research UK, analysed survey responses from 127,793 people aged 16 and above across England, Scotland and Wales, collected between October 2020 and March 2025.

Their analysis showed that nicotine pouch use among 16 to 24-year-olds rose to 4% in 2025, up from just 0.7% in 2022. The increase was most pronounced among young men, with one in 13 men in this age group, or 7.5%, reporting use.

Overall, men accounted for 72% of nicotine pouch users between 2022 and 2025, while 47% were under the age of 25. Dr Tattan-Birch said the growth in use has been driven almost entirely by young people, particularly young men, with usage among adults over 35 remaining low and largely unchanged.

He added that this trend also includes children. Since nicotine pouches are not classified as tobacco or vape products, there are currently no age limits. Advertising is also unrestricted, allowing brightly coloured, sweet-flavoured products to appeal to younger audiences.

Do Nicotine Pouches Help Quit Smoking?

The research found that 69 per cent of pouch users were reported using other nicotine products, while 56 per cent of them smoked, as per the survey from January 2022 to March 2025.

1 in 6, which makes it 16 per cent said they never regularly smoked. "Whether nicotine pouches are good or bad for public health depends on who is using them. If it's a young person who would otherwise start smoking, then the use of pouches might help to reduce harm. However, if it's a person who otherwise would not use nicotine at all, then the potential for harm increases," said Tattan-Birch.

A woman experiencing abdominal discomfort went to her gynecologist for an ultrasound, only to discover something far more startling than a baby. The mom, who shares her story on TikTok under the handle @sandwitchbread, revealed her medical surprise in a video that has now amassed over 1.9 million views. She said she had been struggling with pain and unusual bleeding since giving birth to her two-year-old son and decided to see a gynecologist fearing she might be pregnant again.

During the ultrasound, she noticed something on the screen, but the doctor quickly reassured her it wasn’t a baby. “When my doctor came in to share the results,” the TikToker recalled, “she looked me in the eyes and told me I had a seven-centimeter cyst, about the size of a chicken egg, called a dermoid cyst.”

What Is A Dermoid Cyst?

A dermoid cyst is a pocket of tissue growth that can contain normal body tissues, sometimes including hair, fluid, teeth, or skin. While this TikToker’s cyst was in her uterus, dermoid cysts are most commonly found in the ovaries. They are generally harmless but often require surgical removal. According to the National Cancer Institute, dermoid cysts are present from birth but may not be detected until later in life. These benign tumors originate from embryonic cells that become “trapped” and develop into tissues in the wrong location. Teeth and hair are frequent components, and surgery is usually recommended if the cyst causes symptoms or complications.

Why Do Dermoid Cysts Have Hair and Teeth?

Dermoid cysts develop hair and teeth because they arise from trapped embryonic cells (ectoderm) that can grow into skin, hair follicles, sweat glands, and even teeth, instead of forming the tissues normally found in the ovary or skin. Essentially, they are benign tumors made up of mature but misplaced body tissues from the outer layer of the embryo, which normally forms skin and related structures.

Dermoid Cysts: Symptoms

Most ovarian dermoid cysts remain symptom-free unless complications occur. When symptoms do appear, the most common one reported is lower abdominal pain.

As the cyst enlarges, it can cause noticeable abdominal swelling and problems with the urinary or digestive system.

In more severe cases, individuals might also experience:

• Fever
• Intense abdominal pain
• Unusual vaginal bleeding
• Unexplained weight loss

The Office on Women’s Health notes that cysts on the ovaries can also cause:

• Pressure in the abdomen
• Bloating
• Abdominal swelling
• Pain in the lower abdomen

Dermoid Cysts: Possible Complications

Some potential complications include:

Rupturing of the cyst: Though rare, ovarian dermoid cysts can burst. If the cyst’s contents leak into the abdominal cavity, it may lead to chronic inflammation of the abdominal lining (peritonitis). In some cases, leakage into the intestines or rectum can result in the material being expelled through the anus.

Ovarian torsion: This occurs when the cyst twists the ligaments holding the ovary in place, which can cut off blood supply to the ovary and fallopian tube.

Infection: The risk of infection is around 1–4%. Severe infections may lead to cyst rupture.

Malignant transformation: Dermoid cysts are almost always benign, but in rare instances, they can become cancerous.

A new weight-loss drug often described as the “triple G” treatment because it mimics three hormones linked to hunger and metabolism has delivered striking results in fresh data shared Thursday by its developer, Eli Lilly. In a clinical study involving more than 400 people living with obesity and knee osteoarthritis, the experimental drug retatrutide led to an average weight reduction of 71 pounds, or close to 29% of total body weight, over a period of 16 months, according to figures released by the company. Participants who received retatrutide also reported a 76% drop in knee pain by the end of the study period, based on the same data. So is

What Is Retatrutide?

Retatrutide is an experimental weight-loss drug developed by Eli Lilly and is widely seen as a next-step advancement beyond current GLP-1-based medications such as semaglutide and tirzepatide. While semaglutide acts on a single hormone pathway and tirzepatide works on two, retatrutide targets three.

It activates GLP-1 and GIP, along with an added glucagon pathway, which is why it is sometimes informally referred to as a “GLP-3” drug. Researchers believe this third pathway could explain the greater weight-loss effects seen so far, although retatrutide remains under investigation and has not yet received FDA approval.

Why Is Retatrutide Trending?

Even without regulatory approval, retatrutide has gained attention among gym enthusiasts, fitness creators, and online weight-loss communities. On platforms like TikTok, where direct searches for #reta or #retatrutide are restricted, users often refer to it using coded terms such as “ratatouille.”

At the same time, the drug has been in the news due to growing concerns about counterfeit versions. Reports from the UK recently revealed that authorities seized more than £250,000 worth of fake weight-loss injection pens labelled as tirzepatide and retatrutide from a hidden factory in Northampton. These products are especially concerning because retatrutide is still in clinical trials and has not been approved for use anywhere in the world.

How Is Retatrutide Different Than Other Weight-Loss Drugs?

Retatrutide works by mimicking three hormones that play a role in appetite and metabolism: GLP-1, GIP, and glucagon. In contrast, most weight-loss drugs currently available target only one or two of these pathways. Ozempic and Wegovy, made by Novo Nordisk, copy the effects of GLP-1, a hormone that influences the brain, pancreas, stomach, liver, and muscles, according to the National Institutes of Health.

Mounjaro and Zepbound, on the other hand, act on both GLP-1 and GIP, a hormone involved in blood sugar regulation through insulin stimulation. Retatrutide’s added glucagon effect is key, as glucagon is known to support fat burning, even when the body is at rest. Ozempic and Mounjaro are approved by the FDA for treating Type 2 diabetes, while Wegovy and Zepbound are approved for people with overweight or obesity. As with any prescription drug, it is important for individuals to consult a healthcare professional to determine whether these treatments are appropriate for them.

When Is Retatrutide Expected To Be Available To Consumers?

There is currently no confirmed timeline for when retatrutide might become available by prescription. Its launch will depend on the FDA’s detailed evaluation of clinical trial data once it is formally submitted. Based on current expectations, approval is unlikely before late 2026 and could potentially extend into 2027 or even 2028.